Mitral Valve

The heart's mitral valve is the site of the most surgical valve repairs and valve replacements. After the resounding success of transcatheter aortic valve replacement (TAVR), which now makes up more than 50% of aortic valve replacements, there is wide expectation transcatheter mitral replacements will follow in the next few year. Currently, the most common transcatheter mitral procedure is transcatheter edge-to-edge (TEER) , using the MitraClip or Pascal clip devices. These devices are also being used for transcatheter tricuspid valve repair (TTVR). Other transcatheter mitral repair systems are in trials for minimally invasive annuloplasty and chordae tendineae repair. 

RSS icon

Survival rates similar when treating secondary MR with TEER or surgery

Surgical mitral valve repair, however, was also associated with multiple benefits.

September 7, 2021
A doctor speaking with a patient

TMVR outcomes suffer when patients have heart failure and diabetes—but benefits remain

Overall, the authors emphasized, TMVR helped heart failure patients with and without diabetes.

August 9, 2021
Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings

Next-day discharge after TMVR is on the rise

By 2018, nearly half of all TMVR patients were going home the very next day. Outcomes for these patients have been consistently positive. 

August 9, 2021

TEER shows potential to boost outcomes for cardiogenic shock patients

Cardiogenic shock has been linked to a heightened risk of morbidity and mortality. TEER, it seems, may be able to help provide patients with some relief. 

July 29, 2021
family visits with doctor

How diabetes impacts TEER outcomes

The new analysis, published in JACC: Heart Failure, focused on patient data from the renowned COAPT trial. 

July 27, 2021
Tablet projecting metaphorical medical hologram

Risk score predicts outcomes for heart failure patients undergoing TEER

The new analysis included data from nearly 700 patients who underwent TEER, formerly known as TMVR, over an eight-year period. 

July 1, 2021
With advances and increased experience in the percutaneous coronary intervention (PCI), same-day discharge (SDD) has become increasingly commonplace, but patient selection is key. Antithrombotic therapy may not be necessary for certain transcatheter aortic valve replacement (TAVR) patients, according to a new analysis published in JACC: Cardiovascular Interventions.

Surgery still more common than TMVR among AMI patients, but the gap is shrinking

The study's authors emphasized how important it is for clinicians to work together to determine the best treatment strategy. 

June 10, 2021

Significant MR after TAVR linked to higher mortality rates—but staged interventions may help

Percutaneous edge-to-edge mitral valve repair was associated with improved outcomes among TAVR patients with persistent mitral regurgitation. 

May 14, 2021
Displaying 65 - 72 of 89
Design by Adaptive Theme